Exelixis, Inc. (EXEL): Operating Cash Flow
$884.27M
Year ended 2026-01-02, Fiscal 2025
$1.18B
Trailing 12 months to 2026-07-03
+34.6%
3-year compound annual growth
+33.4%
5-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2026-01-02, Fiscal 2025 | $884.27M | +26.3% | 2026-02-10, From 2025-01-04 |
| 2025-01-03, Fiscal 2024 | $699.97M | +110.0% | 2026-02-10, From 2023-12-30 |
| 2023-12-29 | $333.32M | -8.1% | 2026-02-10, From 2022-12-31 |
| 2022-12-30 | $362.61M | -9.5% | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | $400.80M | +91.8% | 2024-02-06, From 2021-01-02 |
| 2021-01-01, Fiscal 2020 | $208.98M | -60.3% | 2023-02-07, From 2020-01-04 |
| 2020-01-03, Fiscal 2019 | $526.96M | +26.8% | 2022-02-18, From 2018-12-29 |
| 2018-12-28 | $415.72M | +151.0% | 2021-02-11, From 2018-01-01 |
| 2017-12-29 | $165.61M | -21.3% | 2020-02-25, From 2016-12-31 |
| 2016-12-30 | $210.40M | n/m | 2019-02-22, From 2016-01-02 |
| 2016-01-01, Fiscal 2015 | -$141.05M | n/m | 2018-02-26, From 2015-01-03 |
| 2014-12-31 | -$235.41M | n/m | 2017-02-27, From 2014-01-01 |
| 2013-12-31 | -$198.77M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$123.15M | n/m | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | -$159.23M | n/m | 2014-02-20, From 2011-01-01 |
| 2010-12-31 | -$101.05M | n/m | 2013-02-21, From 2010-01-01 |
| 2009-12-31 | -$14.59M | n/a | 2012-02-22, From 2009-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | 2026-01-02 | $884.27M | +26.3% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $654.33M | -2.9% |
| Moderna, Inc. (MRNA) | 2025-12-31 | -$1.87B | n/m |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $782.70M | +31.5% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $651.56M | +36.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $292.07M | +1.6% |
| Novavax Inc (NVAX) | 2025-12-31 | -$244.63M | n/m |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $347.37M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $117.42M | -33.1% |
Compare EXEL, QGEN, MRNA, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗